| 1067- | VitC, | Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer |
| - | in-vivo, | CRC, | NA |
| 300- | VitC, | ALA, | Combination of High-Dose Parenteral Ascorbate (Vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect But Increased Toxicity in Preclinical Cancer Models |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Ovarian, | PANC1 | - | in-vitro, | Pca, | PC3 |
| 588- | VitC, | MF, | Preparation of magnetic nanoparticle integrated nanostructured lipid carriers for controlled delivery of ascorbyl palmitate |
| 593- | VitC, | MF, | Protective Effect of Ascorbic Acid on Molecular Behavior Changes of Hemoglobin Induced by Magnetic Field Induced by Magnetic Field |
| 580- | VitC, | MF, | Extremely low frequency magnetic field induces oxidative stress in mouse cerebellum |
| - | in-vivo, | Nor, | NA |
| 579- | VitC, | MF, | Effect of Magnetic Field on Ascorbic Acid Oxidase Activity, I |
| - | in-vitro, | NA, | NA |
| 636- | VitC, | Acute Effects of Vitamin C Exposure On Colonic Crypts: Direct Modulation of pH Regulation |
| - | in-vivo, | NA, | NA |
| 616- | VitC, | Suppression of alkaline phosphatase in prostate cancer patients by high dose intravenous Vitamin C Treatment: Three cases |
| - | Case Report, | NA, | NA |
| 615- | VitC, | High Dose IV Vitamin C and Metastatic Breast Cancer: A Case Report |
| - | Case Report, | NA, | NA |
| 614- | VitC, | Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use |
| 613- | VitC, | High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer |
| - | Review, | NA, | NA |
| 612- | VitC, | VitK3, | Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action |
| 611- | VitC, | Characterization of a new malignant human T-cell line (PFI-285) sensitive to ascorbic acid |
| - | in-vitro, | NA, | NA |
| 610- | VitC, | Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues |
| - | in-vitro, | lymphoma, | JPL119 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | Nor, | NA |
| 609- | VitC, | ALA, | VitK3, | Se, | Vitamin C and Cancer: Is There A Use For Oral Vitamin C? |
| 617- | VitC, | Chemo, | The Use of Vitamin C with Chemotherapy in Cancer Treatment: An Annotated Bibliography |
| - | Review, | NA, | NA |
| 607- | VitC, | Intravenously administered vitamin C as cancer therapy: three cases |
| - | Case Report, | NA, | NA |
| 606- | VitC, | Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer |
| - | Review, | NA, | NA |
| 605- | VitC, | Therapeutic Use of Vitamin C in Cancer: Physiological Considerations |
| - | Review, | NA, | NA |
| 600- | VitC, | VitK3, | Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer |
| - | in-vitro, | NA, | NA |
| 599- | VitC, | Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment |
| - | Review, | NA, | NA |
| 598- | VitC, | Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly |
| - | Review, | NA, | NA |
| 597- | VitC, | dietSTF, | GlucDep, | The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness |
| 596- | VitC, | High-Dose Vitamin C in Advanced-Stage Cancer Patients |
| - | Review, | NA, | NA |
| 627- | VitC, | High-Dose Vitamin C for Cancer Therapy |
| - | Review, | NA, | NA |
| 635- | VitC, | VitK3, | The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress |
| - | in-vitro, | NA, | NA |
| 634- | VitC, | Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? |
| - | Analysis, | NA, | NA |
| 633- | VitC, | Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment |
| - | Analysis, | NA, | NA |
| 632- | VitC, | High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients |
| - | Review, | NA, | NA |
| 631- | VitC, | Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2 |
| - | vitro+vivo, | Liver, | NA |
| 630- | VitC, | Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | HT-29 |
| 629- | VitC, | Cu, | Fe, | The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer |
| - | in-vitro, | NA, | NA |
| 628- | VitC, | Mg, | Enhanced Anticancer Effect of Adding Magnesium to Vitamin C Therapy: Inhibition of Hormetic Response by SVCT-2 Activation |
| - | in-vivo, | Colon, | CT26 | - | in-vitro, | NA, | MCF-7 | - | in-vitro, | NA, | SkBr3 |
| 618- | VitC, | Low levels of catalase enzyme make cancer cells vulnerable to high-dose ascorbate |
| 626- | VitC, | Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials |
| - | Review, | NA, | NA |
| 625- | VitC, | The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review |
| 624- | VitC, | Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications |
| - | Review, | NA, | NA |
| 623- | VitC, | The Involvement of Ascorbic Acid in Cancer Treatment |
| - | Review, | NA, | NA |
| 622- | VitC, | Treatment of Pancreatic Cancer with Pharmacological Ascorbate |
| - | vitro+vivo, | PC, | NA |
| 621- | VitC, | Sixteen-Year History with High Dose Intravenous Vitamin C Treatment for Various Types of Cancer and Other Diseases |
| 620- | VitC, | Case Study: High-Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney |
| - | Case Report, | NA, | NA |
| 619- | VitC, | Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress |
| 114- | VitC, | QC, | Chemoprevention of prostate cancer cells by vitamin C plus quercetin: role of Nrf2 in inducing oxidative stress |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 115- | VitD3, | Vitamin D3 Inhibits Hedgehog Signaling and Proliferation in Murine Basal Cell Carcinomas |
| - | in-vivo, | RCC, | NA | - | in-vivo, | BCC, | NA |
| 2171- | VitD3, | Vitamin D and the Immune System |
| - | Analysis, | Nor, | NA |
| 2366- | VitD3, | Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 2369- | VitD3, | Long Non-coding RNA MEG3 Activated by Vitamin D Suppresses Glycolysis in Colorectal Cancer via Promoting c-Myc Degradation |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | RKO |
| 2368- | VitD3, | Vitamin D3 supplementation shapes the composition of gut microbiota and improves some obesity parameters induced by high-fat diet in mice |
| - | in-vivo, | Obesity, | NA |
| 2367- | VitD3, | Vitamin D activates FBP1 to block the Warburg effect and modulate blast metabolism in acute myeloid leukemia |
| - | in-vivo, | AML, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid